Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) has granted 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to continued employment. The grants were made as employment inducements under NASDAQ Rule 5635(c)(4).
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi).
Esperion (NASDAQ: ESPR) ha concesso 49.300 unità di azioni vincolate (RSU) a 15 nuovi dipendenti nell'ambito del suo Piano di Incentivi Azionari di Induzione 2017. Le RSU matureranno il 25% nel primo anniversario della data di inizio maturazione del beneficiario, mentre il restante 75% maturerà in dodici rate trimestrali uguali, subordinatamente alla continuazione del rapporto di lavoro. Le assegnazioni sono state effettuate come incentivi occupazionali ai sensi della Regola NASDAQ 5635(c)(4).
Esperion è un'azienda biofarmaceutica a livello commerciale che sviluppa farmaci orali approvati dalla FDA, da assumere una volta al giorno, non statine, per pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dal CLEAR Cardiovascular Outcomes Trial, che ha coinvolto quasi 14.000 pazienti. L'azienda sta inoltre portando avanti il suo programma di nuova generazione focalizzato sugli inibitori dell'ATP citrato liasi (ACLYi).
Esperion (NASDAQ: ESPR) ha otorgado 49,300 unidades de acciones restringidas (RSU) a 15 nuevos empleados bajo su Plan de Incentivos de Capital de Inducción 2017. Las RSU se consolidarán en un 25% en el primer aniversario de la fecha de inicio de consolidación del beneficiario, y el 75% restante se consolidará en doce cuotas trimestrales iguales, sujeto a la continuidad del empleo. Las concesiones se realizaron como incentivos laborales bajo la Regla NASDAQ 5635(c)(4).
Esperion es una compañía biofarmacéutica en etapa comercial que desarrolla medicamentos orales aprobados por la FDA, de una vez al día y no estatinas, para pacientes con enfermedades cardiovasculares y colesterol LDL elevado. Sus medicamentos cuentan con el respaldo del ensayo CLEAR Cardiovascular Outcomes, que involucró a casi 14,000 pacientes. La empresa también está avanzando en su programa de próxima generación enfocado en inhibidores de la ATP citrato liasa (ACLYi).
에스페리온 (NASDAQ: ESPR)은 2017년 유인 주식 인센티브 계획에 따라 15명의 신규 직원에게 49,300개의 제한 주식 단위(RSU)를 부여했습니다. RSU는 수혜자의 권리 취득 시작일 1주년에는 25%가 취득되며, 나머지 75%는 이후 12개의 동일한 분기별 할부로 취득되며, 계속 고용 조건이 적용됩니다. 이 부여는 NASDAQ 규칙 5635(c)(4)에 따른 고용 유인으로 이루어졌습니다.
에스페리온은 FDA 승인된 경구용, 하루 1회 복용하는 비스타틴계 심혈관 질환 환자의 LDL-C 수치 상승 치료제를 개발하는 상업 단계의 생명공학 제약 회사입니다. 이 약물들은 약 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다. 회사는 또한 ATP 시트르산 분해효소 억제제(ACLYi)에 중점을 둔 차세대 프로그램도 진행 중입니다.
Esperion (NASDAQ : ESPR) a attribué 49 300 unités d'actions restreintes (RSU) à 15 nouveaux employés dans le cadre de son plan d'incitation en actions de 2017. Les RSU seront acquises à hauteur de 25 % à la date anniversaire d'un an du début de la période d'acquisition du bénéficiaire, les 75 % restants seront acquis en douze versements trimestriels égaux par la suite, sous réserve de la poursuite de l'emploi. Les attributions ont été faites en tant qu'incitations à l'emploi conformément à la règle NASDAQ 5635(c)(4).
Esperion est une société biopharmaceutique en phase commerciale développant des médicaments oraux, une fois par jour, non statines, approuvés par la FDA, pour les patients atteints de maladies cardiovasculaires avec un LDL-C élevé. Leurs médicaments sont soutenus par l'étude CLEAR Cardiovascular Outcomes impliquant près de 14 000 patients. La société fait également progresser son programme de nouvelle génération axé sur les inhibiteurs de l'ATP citrate lyase (ACLYi).
Esperion (NASDAQ: ESPR) hat 49.300 Restricted Stock Units (RSUs) an 15 neue Mitarbeiter im Rahmen seines Inducement Equity Incentive Plans von 2017 gewährt. Die RSUs werden zu 25 % am einjährigen Jahrestag des Beginns der Vesting-Periode des Empfängers fällig, die restlichen 75 % werden anschließend in zwölf gleichen vierteljährlichen Raten fällig, vorbehaltlich einer fortgesetzten Beschäftigung. Die Zuteilungen erfolgten als Anreiz im Rahmen der NASDAQ-Regel 5635(c)(4).
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das von der FDA zugelassene orale, einmal täglich einzunehmende nicht-statinbasierte Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C entwickelt. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes-Studie mit fast 14.000 Patienten unterstützt. Das Unternehmen entwickelt zudem sein nächstes Programm, das sich auf ATP-Citrat-Lyase-Inhibitoren (ACLYi) konzentriert.
- None.
- None.
ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
What is the vesting schedule for Esperion's (ESPR) new RSU grants in May 2025?
How many RSUs did Esperion (ESPR) grant to new employees in May 2025?
What is Esperion's (ESPR) main product focus in 2025?
What is Esperion's (ESPR) next-generation research program?
